Oppenheimer notes that Veru (VERU) presented a meta-analysis of results from four prior placebo-controlled Phase 2 and 3 clinical studies of enobosarm at the ObesityWeek meeting. The firm, which remains positive on the opportunity for enobosarm to pair with GLP-1-based therapy to yield higher-quality and more weight loss, would be buyers ahead of January’s top line readout from the Phase 2b QUALITY trial, says the analyst, who keeps an Outperform rating and $5 price target on Veru shares.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERU: